{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-008484","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.011046+00:00","generated_at":"2026-06-25T22:31:45.119325+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcus Q1 net loss $68M; ARC-7 domvanalimab arms continue to differentiate","bullets":["Cash $1.34B, up from $681M due to $725M from Gilead in Jan 2022; funding into 2026.","Q1 revenue $18M (up from $9.5M YoY); net loss improved to $68M from $72.6M YoY.","Third IA of ARC-7: domvanalimab arms showed meaningful differentiation in ORR and DoR vs anti-PD1 alone; no unexpected safety.","Phase 3 STAR-121 (domvanalimab+zim+chemo vs pembro+chemo) for 1L NSCLC PD-L1 all-comers planned Q4 2022.","R&D expenses $61.2M (down from $66.4M) due to cost-sharing with Gilead; G&A increased to $24M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-008484","json":"https://secwatch.observer/filing/0000950170-22-008484.json","markdown":"https://secwatch.observer/filing/0000950170-22-008484.md","text":"https://secwatch.observer/filing/0000950170-22-008484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/0000950170-22-008484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000095017022008484/rcus-20220509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:31:45.119325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}